Status:
UNKNOWN
Is in Vitro Maturation of Oocytes Influenced by the Origin of Gonadotropins Used in Maturation Medium: is There a Difference in Efficiency When Using Urinary Versus Recombinant Produced Follicle Stimulating Hormone and Human Chorionic Gonadotropin
Lead Sponsor:
Universitair Ziekenhuis Brussel
Conditions:
In Vitro Maturation of Oocytes
Eligibility:
FEMALE
18-36 years
Brief Summary
Standard IVM currently contains urinary purified hormones which might contain contaminants possibly affecting maturation of embryo development. The investigators will test if the efficiency in terms o...
Detailed Description
In vitro maturation is a valid option for PCO(S) patients in the daily ART clinic, however maturation and embryologic development are not yet matching the efficiency levels obtained by standard COS tr...
Eligibility Criteria
Inclusion
- PCO(S) patients
- Anti-Mullerian Hormone ≥ 3.6 ng/mL
- Basal Antral Follicle Count ≥ 20
- All ranks of trial
Exclusion
- Surgically obtained semen sample
- Grade 3 or 4 endometriosis, minor or major uterine abnormalities
- Preimplantation Genetic Testing
- Priming with Letrozole
Key Trial Info
Start Date :
April 19 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2023
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT05370794
Start Date
April 19 2022
End Date
June 30 2023
Last Update
November 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ Brussel
Brussels, Belgium, 1090